| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Diabetes type 1 | 76 | 33 | |
| Diabetes type 2 | 31 | 4 | |
| Cystic fibrosis-related diabetes | 2 | 1 | |
| Addison's disease | 1 | 3 | |
| Elevated blood sugar (hyperglycemia) | 1 | 0 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Low blood sugar (hypoglycemia) | 8 | |
| Reactive hypoglycemia | 2 | |
| Weight gain | 2 | |
| Elevated blood sugar (hyperglycemia) | 1 | |
| Injection site bleeding | 1 | |
| Injection site scar | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 2 | |
| Moderate | 4 | |
| Mild | 17 | |
| None | 24 |
Member evaluations
mcvet
evaluated on May 06, 2012
- Perceived effectiveness for diabetes type 1: Major
- Side effects: Moderate
Ern
evaluated on Sep 29, 2011
- Perceived effectiveness for diabetes type 1: Major
- Side effects: Moderate
Beaker
evaluated on Feb 24, 2009
- Perceived effectiveness for Other: Major
- Side effects: Mild